PRELID1P3

Across TCGA pan-cancer cohorts, PRELID1P3 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PRELID1P3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRELID1P3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRELID1P3 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRC, BRCA, and THCA are the cancer types where PRELID1P3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRELID1P3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	+0.256	<.001	12	view →
BRCA	Female	All	+0.159	.022	4	view →
THCA	Male	All	−0.090	.002	2	view →
CHOL	All	All	+0.064	.023	1	view →
KICH	All	All	−0.054	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PRELID1P3–KIRC

Open the KIRC breakdown →